



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



JK-P3

Item No. 37555

CAS Registry No.: 942655-44-9
Formal Name: 3,4-dimethoxy-N-(5-phenyl-1H-pyrazol-3-yl)-benzamide
MF: C₁₈H₁₇N₃O₃
FW: 323.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JK-P3 is supplied as a solid. A stock solution may be made by dissolving the JK-P3 in the solvent of choice, which should be purged with an inert gas. JK-P3 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of JK-P3 in these solvents is approximately 30 mg/ml.

Description

JK-P3 is an inhibitor of the tyrosine kinases VEGFR2, FGFR1, and FGFR3 (IC₅₀s = 7.83, 27, and 5.18 μM, respectively).¹ It decreases VEGF-A-induced VEGFR2 phosphorylation in human umbilical vein endothelial cells (HUVECs) when used at a concentration 10 μM. JK-P3 decreases the proliferation of HCT116, SW480, and HT-29 colon cancer cells (IC₅₀s = 24.26, 27.2, and 29.65 μM, respectively), as well as A549 lung cancer cells (IC₅₀ = 30.49 μM).² It decreases wound closure percentage in a scratch assay, as well as endothelial branch length and branch points formed by VEGF-A-stimulated HUVECs when used at a concentration of 10 μM.¹

References

1. Kankanala, J., Latham, A.M., Johnson, A.P., *et al.* A combinatorial *in silico* and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. *Br. J. Pharmacol.* **166**(2), 737-748 (2012).
2. Dong, Y., Liu, M., Mao, Y., *et al.* Discovery of 2-(isoxazol-5-yl)phenyl 3,4-dihydroxybenzoate as a potential inhibitor for the Wnt/β-catenin pathway. *Bioorg. Chem.* **128**, 106116 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/06/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM